Collectively, these findings suggest that although baseline endogenous serum EPO concentration ≤ 200 U/L appears to be predictive of higher efficacy with ESA, luspatercept is a promising therapeutic option for the treatment of anemia in NTD patients with LR-MDS, regardless of serum EPO levels. Here, EPO is linked to myelodysplastic syndrome.